Amneal Pharmaceuticals(US:AMRX)2025-02-28 19:21Financial Performance & Growth - Amneal reported strong 2024 net revenue of $2.8 billion, a 17% increase year-over-year, and adjusted EBITDA of $627 million, a 12% increase year-over-year[9] - The company achieved broad-based double-digit revenue growth across all three business segments in 2024: Affordable Medicines +15%, Specialty +14%, and AvKARE +25%[9] - Net leverage was reduced to 3.9x, below the expected 4x, and down from 4.8x at the end of 2023[9] - Amneal paid down $182 million in debt over the course of 2024[9] - The company projects 2025 net revenue between $3.0 and $3.1 billion (7% to 11% growth) and adjusted EBITDA between $650 and $675 million (4% to 8% growth)[52] Strategic Initiatives & Portfolio Expansion - Amneal is entering a new chapter of growth in 2025 and beyond, focusing on becoming a global biopharmaceutical company[12, 14] - The company is expanding its biosimilar portfolio from three biosimilars to six biosimilars across eight product presentations expected by 2027[9, 36] - A collaboration with Metsera is in place for developing next-generation obesity therapies (GLP-1s)[9, 31] Segment Performance & Outlook - Affordable Medicines generated $1.685 billion in revenue in 2024 and is projected to have high single-digit growth[22] - Specialty revenue was $446 million in 2024, with a high single-digit growth projection, aiming for $500M+ revenue by 2027[22] - AvKARE achieved $663 million in revenue in 2024 and is projected to have double-digit growth, targeting $900M+ revenue by 2027[22]